At $24 billion in annual revenue, growth has to come from somewhere. Just like any other large conglomerate, Thermo Fisher is constantly testing new business lines to sustain overall product and service portfolio growth into the future. Recently, the company announced its advancements in genotype by sequencing (GBS) solutions for canines and felines...
Sorry, you need to subscribe to read this article.
If you would like to access this article, please subscribe below.
Premium subscribers receive complete access to our site content which includes market research and insights as well as coverage of the most important news, issues and events related to the healthcare technology industry.